Alcoholic Hepatitis - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 67
Inquire Before Buying

Global Markets Direct's, ‘Alcoholic Hepatitis - Pipeline Review, H2 2016', provides an overview of the Alcoholic Hepatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis

  • The report reviews pipeline therapeutics for Alcoholic Hepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Alcoholic Hepatitis therapeutics and enlists all their major and minor projects

  • The report assesses Alcoholic Hepatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Alcoholic Hepatitis

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Alcoholic Hepatitis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Alcoholic Hepatitis - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Alcoholic Hepatitis Overview 7
Therapeutics Development 8
Pipeline Products for Alcoholic Hepatitis - Overview 8
Pipeline Products for Alcoholic Hepatitis - Comparative Analysis 9
Alcoholic Hepatitis - Therapeutics under Development by Companies 10
Alcoholic Hepatitis - Therapeutics under Investigation by Universities/Institutes 11
Alcoholic Hepatitis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Alcoholic Hepatitis - Products under Development by Companies 14
Alcoholic Hepatitis - Products under Investigation by Universities/Institutes 15
Alcoholic Hepatitis - Companies Involved in Therapeutics Development 16
Alfact Innovation 16
Conatus Pharmaceuticals Inc. 17
Generon (Shanghai) Corporation Ltd. 18
Genextra S.p.a. 19
Gilead Sciences, Inc. 20
GRI Bio, Inc. 21
Immuron Limited 22
Promethera Biosciences S.A. 23
Verlyx Pharma Inc. 24
Alcoholic Hepatitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
ALF-5755 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
emricasan - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
F-652 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
GRI-0621 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HepaStem - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
IMM-124E - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
obeticholic acid - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
pentamidine isethionate - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
PMKM-02GI1 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
selonsertib - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Alcoholic Hepatitis - Dormant Projects 63
Alcoholic Hepatitis - Product Development Milestones 64
Featured News & Press Releases 64
Sep 11, 2013: Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure Patients 64
Sep 10, 2013: Conatus Pharmaceuticals' Emricasan Dosed in First Patient in Mayo Clinic Phase 2 Trial in Severe Alcoholic Hepatitis Population 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Alcoholic Hepatitis, H2 2016 8
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Alcoholic Hepatitis - Pipeline by Alfact Innovation, H2 2016 16
Alcoholic Hepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2016 17
Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 18
Alcoholic Hepatitis - Pipeline by Genextra S.p.a., H2 2016 19
Alcoholic Hepatitis - Pipeline by Gilead Sciences, Inc., H2 2016 20
Alcoholic Hepatitis - Pipeline by GRI Bio, Inc., H2 2016 21
Alcoholic Hepatitis - Pipeline by Immuron Limited, H2 2016 22
Alcoholic Hepatitis - Pipeline by Promethera Biosciences S.A., H2 2016 23
Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc., H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Alcoholic Hepatitis - Dormant Projects, H2 2016 63

List of Figures

Number of Products under Development for Alcoholic Hepatitis, H2 2016 8
Number of Products under Development for Alcoholic Hepatitis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Top 10 Targets, H2 2016 26
Number of Products by Stage and Top 10 Targets, H2 2016 26
Number of Products by Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32
  • Global Clostridium Difficile Treatment Market Research Report 2017
    Published: 20-Jul-2017        Price: US 2900 Onwards        Pages: 118
    In this report, the global Clostridium Difficile Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Clostridium Difficile Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Eu......
  • Global Liver Disease Treatment Market 2017-2021
    Published: 19-Jul-2017        Price: US 3500 Onwards        Pages: 98
    Liver is the largest organ of the body and can completely recover from damage. However, continuous strain on the liver, when treatment is delayed, for a prolonged period of time can lead to severe damage to the liver and can even be fatal. Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as Ind......
  • Asia-Pacific Varicose Vein Treatment Market Report 2017
    Published: 19-Jul-2017        Price: US 4000 Onwards        Pages: 113
    In this report, the Asia-Pacific Varicose Vein Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Varicose Vein Treatment for these regions, from 2012 to 2022 (forecast) , including - China - Japan - So......
  • Secondary Hyperparathyroidism - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 38
    Secondary Hyperparathyroidism - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H2 2017, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape. Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too l......
  • Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 26
    Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017, provides an overview of the Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline landscape. Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. ......
  • Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 161
    Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape. Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, con......
  • Amyloidosis - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 157
    Amyloidosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Pipeline Review, H2 2017, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predi......
  • Phenylketonuria (PKU) - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 47
    Phenylketonuria (PKU) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria (PKU) - Pipeline Review, H2 2017, provides an overview of the Phenylketonuria (PKU) (Metabolic Disorders) pipeline landscape. Phenylketonuria (also called PKU), is a rare inherited disorder that causes an amino acid called phenylalanine to build up in body. Symptoms include intellectual disability, ......
  • Sarcopenia - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 2000 Onwards        Pages: 60
    Sarcopenia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2017, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape. Sarcopenia is defined as the loss of mass and muscular function with age. Symptoms include obesity, difficulty walking or moving about, lack of strength and respiratory problems. Treatment includes med......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs